Cargando…

Using medication utilization information to develop an asthma severity classification model

BACKGROUND: Claims data are currently widely used as source data in asthma studies. However, the insufficient information in claims data related to level of asthma severity may negatively impact study findings. The present study develops and validates an asthma severity classification model that use...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Tsung-Hsien, Fu, Pin-Kuei, Tung, Yu-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738714/
https://www.ncbi.nlm.nih.gov/pubmed/29262809
http://dx.doi.org/10.1186/s12911-017-0571-9
_version_ 1783287746023915520
author Yu, Tsung-Hsien
Fu, Pin-Kuei
Tung, Yu-Chi
author_facet Yu, Tsung-Hsien
Fu, Pin-Kuei
Tung, Yu-Chi
author_sort Yu, Tsung-Hsien
collection PubMed
description BACKGROUND: Claims data are currently widely used as source data in asthma studies. However, the insufficient information in claims data related to level of asthma severity may negatively impact study findings. The present study develops and validates an asthma severity classification model that uses medication utilization in Taiwan National Health Insurance claims data. METHODS: The National Health Insurance Research Database was used for the years 2006–2012 and included a total of 7221 patients newly diagnosed with asthma in 2007 for model development and in 2008 for model validation. The medication utilization of patients during the first year after the index date was used to classify level of severity, and the acute exacerbation of asthma during the second through fourth years after the index date was used as the outcome variable. Three models were developed, with subjects classified into four, three, and two groups, respectively. The area under the receiver operating characteristic curve (AUC) and the Kaplan-Meier survival curve were used to compare the performances of the classification models. RESULTS: In development data, the distribution of subjects and acute exacerbation rate among the stage 1 to stage 4 were: 62.71%, 5.54%, 22.79%, and 8.96%, and 8.17%, 9.55%, 11.97%, and 14.91%, respectively. The results also showed the higher severity groups to be more prone to being prescribed oral corticosteroids for asthma control, while lower severity groups were more likely to be prescribed short-acting medication and inhaled corticosteroid treatment. Furthermore, the results of survival analysis showed two-group classification was recommended and yield moderate performance (AUC = 0.671). In validation data, the distribution of subjects, acute exacerbation rates, and medication uses among stages were similar to those in development data, and the results of survival analysis were also the same. CONCLUSIONS: Understanding asthma severity is critical to conducting effective, scholarly research on asthma, which currently uses claims data as a primary data source. The model developed in the present study not only overcomes a gap in the current literature but also provides an opportunity to improve the validity and quality of claims-data-based asthma studies.
format Online
Article
Text
id pubmed-5738714
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57387142017-12-21 Using medication utilization information to develop an asthma severity classification model Yu, Tsung-Hsien Fu, Pin-Kuei Tung, Yu-Chi BMC Med Inform Decis Mak Research Article BACKGROUND: Claims data are currently widely used as source data in asthma studies. However, the insufficient information in claims data related to level of asthma severity may negatively impact study findings. The present study develops and validates an asthma severity classification model that uses medication utilization in Taiwan National Health Insurance claims data. METHODS: The National Health Insurance Research Database was used for the years 2006–2012 and included a total of 7221 patients newly diagnosed with asthma in 2007 for model development and in 2008 for model validation. The medication utilization of patients during the first year after the index date was used to classify level of severity, and the acute exacerbation of asthma during the second through fourth years after the index date was used as the outcome variable. Three models were developed, with subjects classified into four, three, and two groups, respectively. The area under the receiver operating characteristic curve (AUC) and the Kaplan-Meier survival curve were used to compare the performances of the classification models. RESULTS: In development data, the distribution of subjects and acute exacerbation rate among the stage 1 to stage 4 were: 62.71%, 5.54%, 22.79%, and 8.96%, and 8.17%, 9.55%, 11.97%, and 14.91%, respectively. The results also showed the higher severity groups to be more prone to being prescribed oral corticosteroids for asthma control, while lower severity groups were more likely to be prescribed short-acting medication and inhaled corticosteroid treatment. Furthermore, the results of survival analysis showed two-group classification was recommended and yield moderate performance (AUC = 0.671). In validation data, the distribution of subjects, acute exacerbation rates, and medication uses among stages were similar to those in development data, and the results of survival analysis were also the same. CONCLUSIONS: Understanding asthma severity is critical to conducting effective, scholarly research on asthma, which currently uses claims data as a primary data source. The model developed in the present study not only overcomes a gap in the current literature but also provides an opportunity to improve the validity and quality of claims-data-based asthma studies. BioMed Central 2017-12-20 /pmc/articles/PMC5738714/ /pubmed/29262809 http://dx.doi.org/10.1186/s12911-017-0571-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Yu, Tsung-Hsien
Fu, Pin-Kuei
Tung, Yu-Chi
Using medication utilization information to develop an asthma severity classification model
title Using medication utilization information to develop an asthma severity classification model
title_full Using medication utilization information to develop an asthma severity classification model
title_fullStr Using medication utilization information to develop an asthma severity classification model
title_full_unstemmed Using medication utilization information to develop an asthma severity classification model
title_short Using medication utilization information to develop an asthma severity classification model
title_sort using medication utilization information to develop an asthma severity classification model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738714/
https://www.ncbi.nlm.nih.gov/pubmed/29262809
http://dx.doi.org/10.1186/s12911-017-0571-9
work_keys_str_mv AT yutsunghsien usingmedicationutilizationinformationtodevelopanasthmaseverityclassificationmodel
AT fupinkuei usingmedicationutilizationinformationtodevelopanasthmaseverityclassificationmodel
AT tungyuchi usingmedicationutilizationinformationtodevelopanasthmaseverityclassificationmodel